Meningococcal Vaccines Market: By Type (Meningococcal Conjugate Vaccines, Meningococcal Polysaccharide Vaccine, Serogroup B Meningococcal Vaccine), By End user (Hospitals, Clinic, Others)and By Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Meningococcal Vaccine Market size was valued at USD 3.17 billion in 2023 and is expected to reach USD 6.92 billion in 2030, growing at a CAGR of 10.14% from 2024 to 202930. Meningococcal disease is a fatal disease caused by Neisseria Meningitides, which causes potential infection in the meninges, the thin layers of connective tissues surrounding the spinal cord and brain. Common symptoms are bacteremia, pneumonia, and meningitis associated with neck stiffness, nausea, high fever, vomiting, confusion, rashes, and lethargy. The surge in the incidence of meningococcal disease is expected to play a vital role in growth of the global meningococcal vaccines market. Meningococcal meningitis is a major public health concern. Various treatment approaches with reasonable costs have been established, however they continue to result in a high fatality rate. In newborns and young children, they can have long-term neurological repercussions.

According to a WHO estimate, 50 percent of meningitis cases occur in children under the age of five. The next susceptible age group is 15-19 years. Meningitis has negatively impacted humanity, so various multinational private agencies have stepped up to create a vaccine. Meningococcal vaccines are available in four different categories. Meningitis A (MenA) and three Conjugate MenACWY vaccines are available. Furthermore, growing awareness among the people regarding the seriousness of the disease, government initiatives, increased R&D investments by various players, and introduction of advanced vaccines are expected to boost the growth of the meningococcal vaccines market. However, lack of awareness, the high cost of vaccines, unfavourable regulatory conditions are restraining of global meningococcal vaccines market.

Meningococcal Vaccines Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

10.14%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Meningococcal Vaccines Market Dynamics

Rise in incidence and mortality rate of meningococcal disease is expected to create lucrative growth opportunities for the global market. Favourable government initiatives are expected create awareness among people. For example, by 2018 Men conjugate vaccines programmes in Africa is anticipated to prevent around 1, 23, 000 deaths. Meningococcal vaccine market is high consolidated market with very few market players. It is experiencing at rapid growth due to new products and it is expected to experience tremendous growth due to new entrants into the market during the forecast period.

Meningococcal Vaccines Market Segmentation

By Type
  • Meningococcal Conjugate Vaccines
  • Meningococcal Polysaccharide Vaccine
  • Serogroup B Meningococcal Vaccine
By End User
  • Hospitals
  • Clinic
  • Others

Frequently Asked Questions

The meningococcal vaccines market size was valued at USD 3.17 billion in 2023

The meningococcal vaccines market key players are: GlaxoSmithKline plc. (UK) JN-International Medical Corporation (U.S.) Novartis International AG (Switzerland) Sanofi (France) Pfizer, Inc. (U.S.) Baxter International, Inc. (U.S.)

The meningococcal vaccines market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Meningococcal Vaccines Market Introduction 
2.1.Global Meningococcal Vaccines Market  - Taxonomy
2.2.Global Meningococcal Vaccines Market  - Definitions
2.2.1. Type 
2.2.2.End User
2.2.3.Region
3. Global Meningococcal Vaccines Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID-19 on Market
4. Global Meningococcal Vaccines Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Meningococcal Vaccines Market  By  Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Meningococcal Conjugate Vaccines
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Meningococcal Polysaccharide Vaccine
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Serogroup B Meningococcal Vaccine
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6. Global Meningococcal Vaccines Market  By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Hospitals
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Clinic
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Others
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7. Global Meningococcal Vaccines Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8. North America Meningococcal Vaccines Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1.  Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Meningococcal Conjugate Vaccines
8.1.2.Meningococcal Polysaccharide Vaccine
8.1.3.Serogroup B Meningococcal Vaccine
8.2.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Hospitals
8.2.2.Clinic
8.2.3.Others
8.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9. Europe Meningococcal Vaccines Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1.  Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Meningococcal Conjugate Vaccines
9.1.2.Meningococcal Polysaccharide Vaccine
9.1.3.Serogroup B Meningococcal Vaccine
9.2.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Hospitals
9.2.2.Clinic
9.2.3.Others
9.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10. Asia Pacific (APAC) Meningococcal Vaccines Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1.  Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Meningococcal Conjugate Vaccines
10.1.2.Meningococcal Polysaccharide Vaccine
10.1.3.Serogroup B Meningococcal Vaccine
10.2.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hospitals
10.2.2.Clinic
10.2.3.Others
10.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11. Middle East and Africa (MEA) Meningococcal Vaccines Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1.  Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Meningococcal Conjugate Vaccines
11.1.2.Meningococcal Polysaccharide Vaccine
11.1.3.Serogroup B Meningococcal Vaccine
11.2.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hospitals
11.2.2.Clinic
11.2.3.Others
11.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12. Latin America Meningococcal Vaccines Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1.  Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Meningococcal Conjugate Vaccines
12.1.2.Meningococcal Polysaccharide Vaccine
12.1.3.Serogroup B Meningococcal Vaccine
12.2.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hospitals
12.2.2.Clinic
12.2.3.Others
12.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.GlaxoSmithKline plc. (UK)
13.2.2.JN-International Medical Corporation (U.S.)
13.2.3.Novartis International AG (Switzerland)
13.2.4.Sanofi (France)
13.2.5.Pfizer, Inc. (U.S.)
13.2.6.Baxter International, Inc. (U.S.)
14. Research Methodology 
15. Appendix and Abbreviations 
  • GlaxoSmithKline plc. (UK)
  • JN-International Medical Corporation (U.S.)
  • Novartis International AG (Switzerland)
  • Sanofi (France)
  • Pfizer, Inc. (U.S.)
  • Baxter International, Inc. (U.S.)

Adjacent Markets